Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 37  |  Issue : 3  |  Page : 349-354

Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial


1 Department of General Surgery, College of Medicine, Ain-Shams University, Cairo; General and Laparoscopic Surgery, Abha Private Hospital, Abha
2 Department of General Surgery, College of Medicine, Ain-Shams University, Cairo, Egypt

Correspondence Address:
Tarek A.O Abouzeid
Department of General and Laparoscopic Surgery, College of Medicine, Ain-Shams University, Cairo, 11566, Egypt

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejs.ejs_29_18

Rights and Permissions

Background In the recent era, laparoscopic sleeve gastrectomy (LSG) had emerged as a safe and effective bariatric procedure. Rapid weight loss is associated with deranged cholesterol metabolism in the form of gallstones. Several studies have shown that ursodeoxycholic acid (UDCA) has a prophylactic role after gastric bypass, vertical banded gastroplasty, and adjustable gastric banding. Yet, data about its effect after LSG are scarce. In this study, we tried to unveil the prophylactic role of UDCA in the prevention of post-LSG gallstones. Materials and methods This two-center prospective randomized controlled trial had been conducted at Abha Private Hospital, Saudi Arabia, and Ain-Shams University hospitals, Egypt, from May 2016 to June 2017 on 89 post-LSG patients. After block randomization, patients were allocated into either group A (UDCA treatment) or group B (control). UDCA was prescribed as 250 mg twice daily for 12 months or until the development of gallstones. Results A total of 44 patients were included in group A and 45 patients were included in group B. There was no significant difference between both the groups regarding the baseline parameters. At the sixth month, group A showed a significantly lower incidence of gallstones (6.8 vs. 22.2% in group B; P=0.028). This pattern was maintained till the 12th month (5.8 vs. 14.7%; P=0.031). The overall percentage of gallstones was 23.5% (20/85); it was significantly higher in the first 6 months than in the second 6 months (14.6 vs. 9.7%; P=0.043). Conclusion UDCA is a safe prophylactic measure against gallstones formation and should be integrated into the post-LSG prescription.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed179    
    Printed2    
    Emailed0    
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal